AU3348700A - Compounds which inhibit leukocyte adhesion mediated by vla-4 - Google Patents
Compounds which inhibit leukocyte adhesion mediated by vla-4Info
- Publication number
- AU3348700A AU3348700A AU33487/00A AU3348700A AU3348700A AU 3348700 A AU3348700 A AU 3348700A AU 33487/00 A AU33487/00 A AU 33487/00A AU 3348700 A AU3348700 A AU 3348700A AU 3348700 A AU3348700 A AU 3348700A
- Authority
- AU
- Australia
- Prior art keywords
- vla
- compounds
- leukocyte adhesion
- adhesion mediated
- inhibit leukocyte
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/04—Artificial tears; Irrigation solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/46—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with hetero atoms directly attached to the ring nitrogen atom
- C07D207/48—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
- C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06078—Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Neurosurgery (AREA)
- Pulmonology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physical Education & Sports Medicine (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Rheumatology (AREA)
- Immunology (AREA)
- Vascular Medicine (AREA)
- Pain & Pain Management (AREA)
- Heart & Thoracic Surgery (AREA)
- Ophthalmology & Optometry (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US23747399A | 1999-01-25 | 1999-01-25 | |
| US09237473 | 1999-01-25 | ||
| PCT/US2000/001603 WO2000043415A1 (en) | 1999-01-25 | 2000-01-21 | Compounds which inhibit leukocyte adhesion mediated by vla-4 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU3348700A true AU3348700A (en) | 2000-08-07 |
Family
ID=22893870
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU33487/00A Abandoned AU3348700A (en) | 1999-01-25 | 2000-01-21 | Compounds which inhibit leukocyte adhesion mediated by vla-4 |
Country Status (9)
| Country | Link |
|---|---|
| EP (1) | EP1150997A1 (en) |
| JP (1) | JP2002539080A (en) |
| CN (1) | CN1185250C (en) |
| AR (1) | AR029611A1 (en) |
| AU (1) | AU3348700A (en) |
| CA (1) | CA2359114A1 (en) |
| HK (1) | HK1044549B (en) |
| MX (1) | MXPA01007394A (en) |
| WO (1) | WO2000043415A1 (en) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2200617B1 (en) | 2001-01-19 | 2005-05-01 | Almirall Prodesfarma, S.A. | DERIVATIVES OF UREA AS ANTAGONISTS OF INTEGRINAS ALPHA 4. |
| JP2005022976A (en) * | 2001-07-18 | 2005-01-27 | Ajinomoto Co Inc | Carboxylic acid derivative |
| EP1450901A4 (en) | 2001-12-10 | 2005-05-25 | Bristol Myers Squibb Co | (1-phenyl-2-heteroaryl)ethyl-guanidine compounds as inhibitors of mitochondrial f1f0 atp hydrolase |
| MXPA05007843A (en) * | 2003-01-24 | 2005-10-18 | Elan Pharm Inc | Composition for and treatment of demyelinating diseases and paralysis by administration of remyelinating agents. |
| CA2522084A1 (en) * | 2003-04-10 | 2004-10-28 | Amgen Inc. | Cyclic amine derivatives and their use in the treatment of inflammation-related disorders mediated by bradykinin |
| JP2019530678A (en) * | 2016-09-18 | 2019-10-24 | エイチ リー モフィット キャンサー センター アンド リサーチ インスティテュート インコーポレイテッド | YAP1 inhibitor targeting the interaction of YAP1 with OCT4 |
| PE20211450A1 (en) | 2018-03-14 | 2021-08-05 | H Lee Moffitt Cancer Ct & Res | YAP1 INHIBITORS DIRECTING THE INTERACTION OF YAP1 WITH OCT4 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1102316A (en) * | 1975-12-09 | 1981-06-02 | Shosuke Okamoto | N su2 xx-arylsulfonyl-l-argininamides and the pharmaceutically acceptable salts thereof |
| FR2679903B1 (en) * | 1991-08-02 | 1993-12-03 | Elf Sanofi | DERIVATIVES OF N-SULFONYL INDOLINE CARRYING AN AMIDIC FUNCTION, THEIR PREPARATION, THE PHARMACEUTICAL COMPOSITIONS CONTAINING SAME. |
| AU1354292A (en) * | 1991-03-18 | 1992-10-21 | Pentapharm Ag | Parasubstituted phenylalanine derivates |
| DE69530392D1 (en) * | 1994-07-11 | 2003-05-22 | Athena Neurosciences Inc | INHIBITORS OF LEUKOCYTE ADHESION |
| US6306840B1 (en) * | 1995-01-23 | 2001-10-23 | Biogen, Inc. | Cell adhesion inhibitors |
| EP1001764A4 (en) * | 1997-05-29 | 2005-08-24 | Merck & Co Inc | Heterocyclic amides as cell adhesion inhibitors |
| WO1998053817A1 (en) * | 1997-05-29 | 1998-12-03 | Merck & Co., Inc. | Biarylalkanoic acids as cell adhesion inhibitors |
| NZ502582A (en) * | 1997-07-31 | 2002-07-26 | American Home Prod | Substituted phenylalanine type compounds which inhibit leukocyte adhesion mediated by VLA-4 |
-
2000
- 2000-01-21 JP JP2000594831A patent/JP2002539080A/en active Pending
- 2000-01-21 AU AU33487/00A patent/AU3348700A/en not_active Abandoned
- 2000-01-21 WO PCT/US2000/001603 patent/WO2000043415A1/en not_active Ceased
- 2000-01-21 CA CA002359114A patent/CA2359114A1/en not_active Abandoned
- 2000-01-21 MX MXPA01007394A patent/MXPA01007394A/en not_active IP Right Cessation
- 2000-01-21 CN CNB008031037A patent/CN1185250C/en not_active Expired - Fee Related
- 2000-01-21 EP EP00911618A patent/EP1150997A1/en not_active Withdrawn
- 2000-01-21 HK HK02106216.3A patent/HK1044549B/en not_active IP Right Cessation
- 2000-01-24 AR ARP000100290A patent/AR029611A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2000043415A1 (en) | 2000-07-27 |
| CN1340058A (en) | 2002-03-13 |
| CN1185250C (en) | 2005-01-19 |
| EP1150997A1 (en) | 2001-11-07 |
| JP2002539080A (en) | 2002-11-19 |
| HK1044549A1 (en) | 2002-10-25 |
| CA2359114A1 (en) | 2000-07-27 |
| AR029611A1 (en) | 2003-07-10 |
| MXPA01007394A (en) | 2002-04-09 |
| HK1044549B (en) | 2005-05-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2623900A (en) | Compounds which inhibit leukocyte adhesion mediated by vla-4 | |
| IL133641A0 (en) | Compounds which inhibit leukocyte adhesion mediated by vla-4 | |
| ZA986834B (en) | Compounds which inhibit leukocyte adhesion mediated by VLA-4. | |
| HUP0002680A3 (en) | Benzyl compounds which inhibit leukocyte adhesion mediated by vla-4 | |
| IL133638A0 (en) | 4-amino-phenylalanine type compounds which inhibit leukocyte adhesion mediated by vla-4 | |
| IL133636A0 (en) | Carbamyloxy compounds which inhibit leukocyte adhesion mediated by vla-4 | |
| ZA986827B (en) | Substituted phenylalanine type compounds which inhibit leukocyte adhesion mediated by VLA-4. | |
| AU3348800A (en) | Multicyclic compounds which inhibit leukocyte adhesion mediated by vla-4 | |
| IL133637A0 (en) | Sulfonylated dipeptide compounds which inhibit leukocyte adhesion mediated by vla-4 | |
| AU1278701A (en) | Novel compounds | |
| AU2408300A (en) | Novel compounds | |
| AUPQ441499A0 (en) | Novel compound | |
| AU2623800A (en) | Pyroglutamic acid derivatives and related compounds which inhibit leukocyte adhesion mediated by vla-4 | |
| AU3348700A (en) | Compounds which inhibit leukocyte adhesion mediated by vla-4 | |
| AU6517800A (en) | Ntr3, a member of the tnf-receptor supergene family | |
| AU4132200A (en) | Novel compounds | |
| AU2109700A (en) | Novel compounds | |
| HK1026218A (en) | Compounds which inhibit leukocyte adhesion mediated by vla-4 | |
| HK1026219A (en) | Benzyl compounds which inhibit leukocyte adhesion mediated by vla-4 | |
| AU4156800A (en) | Novel compounds | |
| AU2288900A (en) | Novel compounds | |
| HK1026424A (en) | Carbamyloxy compounds which inhibit leukocyte adhesion mediated by vla-4 | |
| HK1026217A (en) | 4-amino-phenylalanine type compounds which inhibit leukocyte adhesion mediated by vla-4 | |
| HK1025976A (en) | Dipeptide compounds which inhibit leukocyte adhesion mediated by vla-4 | |
| HK1026435A (en) | Substituted phenylalanine type compounds which inhibit leukocyte adhesion mediated by vla-4 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK6 | Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase |